Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Gain Therapeutics (GANX) Other Non Operating Income (2020 - 2025)

Gain Therapeutics has reported Other Non Operating Income over the past 6 years, most recently at -$84781.0 for Q4 2025.

  • Quarterly results put Other Non Operating Income at -$84781.0 for Q4 2025, down 638.02% from a year ago — trailing twelve months through Dec 2025 was -$833673.0 (down 799.86% YoY), and the annual figure for FY2025 was -$833673.0, down 799.86%.
  • Other Non Operating Income for Q4 2025 was -$84781.0 at Gain Therapeutics, down from -$27382.0 in the prior quarter.
  • Over the last five years, Other Non Operating Income for GANX hit a ceiling of $268077.0 in Q1 2024 and a floor of -$620924.0 in Q2 2025.
  • Median Other Non Operating Income over the past 5 years was -$35127.0 (2021), compared with a mean of -$65644.6.
  • Biggest five-year swings in Other Non Operating Income: skyrocketed 725.73% in 2024 and later plummeted 1324.92% in 2025.
  • Gain Therapeutics' Other Non Operating Income stood at -$19675.0 in 2021, then plummeted by 911.13% to -$198939.0 in 2022, then plummeted by 105.34% to -$408507.0 in 2023, then soared by 103.86% to $15758.0 in 2024, then tumbled by 638.02% to -$84781.0 in 2025.
  • The last three reported values for Other Non Operating Income were -$84781.0 (Q4 2025), -$27382.0 (Q3 2025), and -$620924.0 (Q2 2025) per Business Quant data.